Stock Events

Bionano Genomics 

$1.14
932
-$0.02-1.72% Friday 21:00

Statistics

Day High
1.16
Day Low
1.11
52W High
14.45
52W Low
1.04
Volume
892,691
Avg. Volume
1,512,782
Mkt Cap
44.28M
P/E Ratio
-0.16
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-1.24
-0.86
-0.47
-0.09
Expected EPS
-0.87
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BNGO. It's not an investment recommendation.

Analyst Ratings

0$Average Price Target
The highest estimate is $0.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

About

Health Technology
Biotechnology
Professional, Scientific, and Technical Services
Testing Laboratories
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Show more...
CEO
R. Erik Holmlin
Employees
299
Country
US
ISIN
US09075F1075
WKN
000A2JRLZ

Listings